Get the Stockscreener App
28.88
0.24%
0.07
Pre-market:
29.39
0.51
+1.77%
Edgewise Therapeutics Inc stock is traded at $28.88, with a volume of 1.44M.
It is up +0.24% in the last 24 hours and up +1.44% over the past month.
Edgewise Therapeutics Inc is a clinical-stage biopharmaceutical company. It is developing novel therapeutics for muscular dystrophies and serious cardiac conditions. The company's product candidates are Sevasemten, EDG-7500, EDG-003, and EDG-15400. Sevasemten is an orally administered small molecule designed to address the root cause of dystrophinopathies, including Duchenne muscular dystrophy (Duchenne) and Becker muscular dystrophy (Becker). The company's products are currently in different stages of their development, being developed to target key muscle proteins and modulators to address a broad array of muscle diseases.
See More
Previous Close:
$28.81
Open:
$29.93
24h Volume:
1.44M
Relative Volume:
1.16
Market Cap:
$3.06B
Revenue:
-
Net Income/Loss:
$-150.70M
P/E Ratio:
-18.63
EPS:
-1.55
Net Cash Flow:
$-125.67M
1W Performance:
-4.12%
1M Performance:
+1.44%
6M Performance:
+97.54%
1Y Performance:
+17.88%
1-Day Range:
$28.75
$29.93
1-Week Range:
$28.40
$30.46
52-Week Range:
$10.60
$31.82
Edgewise Therapeutics Inc Stock (EWTX) Company Profile
Name
Edgewise Therapeutics Inc
Sector
Industry
Phone
720-262-7002
Address
1715 38TH ST, BOULDER
Compare EWTX vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
EWTX
Edgewise Therapeutics Inc
|
28.88 | 3.05B | 0 | -150.70M | -125.67M | -1.55 |
|
VRTX
Vertex Pharmaceuticals Inc
|
477.89 | 120.48B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
787.50 | 81.05B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
749.56 | 46.33B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
327.30 | 42.26B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
299.02 | 32.87B | 5.36B | 287.73M | 924.18M | 2.5229 |
Edgewise Therapeutics Inc Stock (EWTX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-25-25 | Initiated | Goldman | Neutral |
| Jul-30-25 | Initiated | Raymond James | Strong Buy |
| Jun-30-25 | Initiated | H.C. Wainwright | Buy |
| Apr-30-25 | Initiated | Guggenheim | Buy |
| Apr-02-25 | Downgrade | Scotiabank | Sector Outperform → Sector Perform |
| Mar-07-25 | Initiated | Scotiabank | Sector Outperform |
| Jan-22-25 | Initiated | Stifel | Hold |
| Nov-22-24 | Initiated | Evercore ISI | Outperform |
| Mar-07-24 | Initiated | Piper Sandler | Overweight |
| May-01-23 | Initiated | Truist | Buy |
| Aug-25-22 | Downgrade | Goldman | Neutral → Sell |
| Apr-13-22 | Initiated | RBC Capital Mkts | Outperform |
| Jan-28-22 | Initiated | Goldman | Neutral |
View All
Edgewise Therapeutics Inc Stock (EWTX) Latest News
Edgewise Therapeutics to Present at Leerink Global Healthcare Conference on March 11, 2026 - geneonline.com
Edgewise Therapeutics, Inc. (EWTX) Stock Price, News, Quote & History - Yahoo Finance
Edgewise Therapeutics to Present at the Leerink Global Healthcare Conference on March 11, 2026 - Yahoo Finance
Edgewise Therapeutics, Inc. (EWTX) Stock Analysis: Unpacking A 35.24% Upside Potential - DirectorsTalk Interviews
Becker muscular dystrophy drug prevents decline for 3.5 years in trial - Stock Titan
EWTX Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Edgewise Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules - ChartMill
Citigroup Inc. Sells 186,446 Shares of Edgewise Therapeutics, Inc. $EWTX - MarketBeat
Investor Mood: Will Edgewise Therapeutics Inc stock hit new highs in YEARJuly 2025 Trade Ideas & AI Based Buy/Sell Signal Reports - baoquankhu1.vn
Aug Reactions: Is Edgewise Therapeutics Inc stock forming a cup and handleTrade Exit Report & Community Verified Watchlist Alerts - baoquankhu1.vn
Artisan Partners Limited Partnership Reduces Stake in Edgewise Therapeutics, Inc. $EWTX - MarketBeat
Edgewise Therapeutics (NASDAQ:EWTX) Stock Rating Upgraded by HC Wainwright - MarketBeat
Edgewise Therapeutics (NASDAQ:EWTX) Downgraded to Sell Rating by Wall Street Zen - MarketBeat
Assessing Edgewise Therapeutics (EWTX) Valuation As Earnings And Key Clinical Milestones Draw Closer - Sahm
Evercore Maintains Outperform, PT $45 for Edgewise Therapeutics (EWTX) Feb 2026 - Meyka
Q1 Earnings Estimate for EWTX Issued By HC Wainwright - MarketBeat
Analysts Offer Insights on Healthcare Companies: NovoCure (NVCR) and Edgewise Therapeutics (EWTX) - The Globe and Mail
Edgewise Therapeutics (NASDAQ:EWTX) Posts Earnings Results - MarketBeat
Raymond James reiterates Strong Buy on Edgewise Therapeutics stock By Investing.com - Investing.com Canada
Raymond James reiterates Strong Buy on Edgewise Therapeutics stock - Investing.com UK
Edgewise Therapeutics Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Edgewise Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2025 - marketscreener.com
Stifel raises Edgewise Therapeutics stock price target on trial data timeline - Investing.com Canada
Edgewise Therapeutics Q4 Net Loss Widens From Previous Quarter - marketscreener.com
Earnings Flash (EWTX) Edgewise Therapeutics Posts Q4 Net Loss $0.47 a Share, vs. FactSet Est of $0.40 Loss - marketscreener.com
Edgewise Therapeutics, Inc. SEC 10-K Report - TradingView
Assessing Edgewise Therapeutics (EWTX) Valuation After Strong Multi‑Year Returns And Recent Share Price Momentum - Yahoo Finance
Edgewise Therapeutics Q4 net loss widens vs Q3 as costs rise - TradingView
Edgewise (Nasdaq: EWTX) ups R&D spending as Q4 2025 loss widens - Stock Titan
BRIEF-Edgewise Therapeutics Q4 Operating Income USD -55.979 Million - TradingView
Edgewise Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results with Strong Progress Across Muscular Dystrophy and Cardiovascular Programs - PR Newswire
Edgewise Therapeutics stock hits 52-week high at $31.39 By Investing.com - Investing.com India
Edgewise Therapeutics (NASDAQ:EWTX) Reaches New 52-Week HighStill a Buy? - MarketBeat
Edgewise Therapeutics stock hits 52-week high at $31.39 - Investing.com
Edgewise Therapeutics, Inc. (EWTX) Stock Analysis: Target Price Suggests 26.84% Upside for Biotech Innovator - DirectorsTalk Interviews
How Edgewise Therapeutics Inc. (EWTX) Affects Rotational Strategy Timing - Stock Traders Daily
Edgewise Therapeutics (EWTX) Projected to Post Earnings on Monday - MarketBeat
Published on: 2026-02-21 16:05:11 - mfd.ru
Aberdeen Group plc Has $10.05 Million Holdings in Edgewise Therapeutics, Inc. $EWTX - MarketBeat
Forecast Cut: Will Edgewise Therapeutics Inc benefit from current market trendsJuly 2025 PostEarnings & Weekly Breakout Watchlists - baoquankhu1.vn
Aug Summary: Is FLIC on track to beat earningsWeekly Profit Recap & Step-by-Step Trade Execution Guides - baoquankhu1.vn
Edgewise Therapeutics earnings on deck as pipeline advances By Investing.com - Investing.com South Africa
Edgewise Therapeutics earnings on deck as pipeline advances - Investing.com Nigeria
Edgewise Therapeutics, Inc. (EWTX) Stock Analysis: A High-Potential Biotech Play with 27% Upside - DirectorsTalk Interviews
GSA Capital Partners LLP Increases Holdings in Edgewise Therapeutics, Inc. $EWTX - MarketBeat
Will Edgewise Therapeutics Inc. stock gain from government policiesWeekly Trade Report & AI Forecast Swing Trade Picks - mfd.ru
Published on: 2026-02-16 03:13:40 - mfd.ru
Is Edgewise Therapeutics Inc. gaining market shareJuly 2025 Reactions & Community Trade Idea Sharing Platform - mfd.ru
What is Edgewise Therapeutics Inc.’s book value per share2025 Fundamental Recap & Reliable Entry Point Trade Alerts - mfd.ru
Edgewise Therapeutics (NASDAQ:EWTX) Upgraded at Wall Street Zen - MarketBeat
Edgewise Therapeutics Inc Stock (EWTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.11%
6.00%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):